629 692
of metastases and improves survival: long-term followup of a
randomized clinical trial. J Urol 2009;181:956–62.
[81]
Fossati N, Karnes RJ, Cozzarini C, et al. Assessing the optimal timing for early salvage radiation therapy in patients with prostate-spe- cific antigen rise after radical prostatectomy. Eur Urol 2016;69: 728–33.[82]
Wallis CJ, Mahar AL, Choo R, et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta- analysis. BMJ 2016;352:i851.[83]
Ash D, Flynn A, Battermann J, et al. ESTRO/EAU/EORTC recommen- dations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000;57:315–21.[84]
Grimm P, Billiet I, Bostwick D, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012;109(Suppl 1):22–9.[85]
Buda¨us L, Bolla M, Bossi A, et al. Functional outcomes and compli- cations following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol 2012;61:112–27.
[86]
Martens C, Pond G, Webster D, et al. Relationship of the Interna- tional Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. Brachytherapy 2006;5:9–13.[87]
Vordermark D, Wulf J, Markert K, et al. 3-D conformal treatment of prostate cancer to 74 Gy vs. high-dose-rate brachytherapy boost: a cross-sectional quality-of-life survey. Acta Oncol 2006;45:708–16.
[88]
Hoskin PJ, Columbo A, Henry A, et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol 2013;107:325–32.
[89]
Ramsay CR, Adewuyi TE, Gray J, et al. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation. Health Technol Assess 2015;19:1–490.E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 6 1 8 – 6 2 9
629